The insertion/deletion polymorphism (I/D) of the angiotensin-converting enzyme (ACE) gene has been associated in some studies with a higher prevalence of left ventricular hypertrophy (LVH), but few of them were performed on pharmacologically treated hypertensive patients. The present study was undertaken to determine whether ACE genotype determination could help in the identification of pharmacologically treated hypertensive patients at a higher risk of LVH. Ninety-six consecutive men with essential hypertension were selected for the study. Left ventricular mass (LVM) was assessed by echocardiography and indexed by body surface area and 82 patients were considered suitable for the study. Three groups of patients were defined on the basis of their I/D ACE genotype: DD (n ‫؍‬ 39), ID (n ‫؍‬ 33) and II (n ‫؍‬ 10). There were no statistically significant differences between the three groups regarding to the severity of
Introduction
Left ventricular hypertrophy (LVH) is recognised as an independent risk factor for cardiovascular morbidity and mortality 1 and is a major determinant of prognosis in essential hypertension. The pathophysiology of LVH associated to essential hypertension is heterogeneous and many factors, including those of a genetic nature, contribute to its development. 1 Studies performed in recent years have demonstrated the existence of an angiotensin-converting enzyme (ACE) gene polymorphism that results in three different genotypes: insertion/insertion (II), insertion/deletion (ID) and deletion/deletion (DD). This polymorphism is partially responsible for the great interindividual variability of serum ACE: the DD genotype being associated to higher levels of circulating ACE.
2 Several studies, but not all, have demonstrated an association between the deletion polymorphism and coronary heart disease 3-10 and hypertension. [11] [12] [13] [14] [15] [16] [17] [18] [19] The association between DD genotype and LVH is still controversial. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Differences in methods to assess LVH, gender distribution, ethnics, and presence or absence and type of treatments could explain, at least in part, these discrepancies. It is noteworthy that most of the studies investigating the effect of the ACE polymorphism in the risk of LVH were performed in normotensive or in non-treated hypertensive patients and that only a few of them included different proportions of treated and non-treated hypertensive patients. 22, 23, 25, 26, 29 To the best of our knowledge, only one study looked at the effect of an ACE inhibitor (enalapril) in previously non-treated hypertensive patients. This study found a greater regression of LVH in DD individuals. 31 Therefore, it is possible that ACE inhibitors prevent LVH or regress LVH more effectively in the individuals with the DD genotype, who are at higher risk of LVH. Most patients with essential hypertension will require drug therapy-and many of them a combination of different types of drugs-to control their blood pressure. Because efforts and resources should concentrate in hypertensive patients at highest risk, we wanted to know whether the determination of ACE genotype could help to detect treated patients at higher risk of LVH.
Materials and methods

Patients
Ninety-six consecutive men under 70 years of age with essential hypertension were selected to participate in the study. All patients were controlled at the Hypertension Unit of our 700-bed University Hospital. All patients had been receiving antihypertensive drugs previously to the study. Time of evolution of hypertension was defined from the moment the patient was informed of his condition until inclusion in the study. The period of treatment was defined from the moment when the patient first received antihypertensive drugs until inclusion in the study. Severity of hypertension at diagnosis was defined according to the criteria of the V Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (V JNC): stages 1 to 4. 32 Blood pressure was measured three times on the same day with subjects sitting after a 10-min rest. An experienced research nurse took the blood pressure measurements using a mercury sphygmomanometer. She was unaware of the results of the echocardiographic and ACE analyses. The mean of the three blood pressure measurements was used for the statistical analysis. The degree of control of hypertension for each patient was evaluated according to the blood pressure mean and was classified in one of the following categories: optimal control, blood pressure Ͻ140/90 mm Hg; suboptimal control, systolic blood pressure between 140 and 160 mm Hg and/or diastolic blood pressure between 90 and 95 mm Hg; and insufficient control, systolic blood pressure Ͼ160 mm Hg and/or diastolic blood pressure Ͼ95 mm Hg. Body mass index (BMI) was calculated by the formula:
. Body surface area (BSA) was determined by the usual nomograms from weight (kg) and height (m). Fifty-seven healthy male volunteers matched by age were used as controls to compare the ACE genotype frequencies with that of the group of patients.
Methods
ACE I/D polymorphism:
Genomic DNA was isolated from blood using a Ready Amp Genomic DNA Purification System (Proomega, Madison, WI, USA). The ACE I/D polymorphism was determined by electrophoretic analysis of DNA amplificated by PCR as previously reported. 33 Three groups of patients were defined on the basis of their ACE genotype: DD, ID and II.
Echocardiography: A two-dimensionally guided M-mode echocardiography was performed with an Ultramark 9 system (Advanced Technology Laboratories, Seattle, WA, USA) equipped with a 3.0 MHz probe. Studies were obtained and read by one of three different cardiologists, highly trained in echocardiography. The interobserver variability of these three observers in assessing left ventricular mass (LVM) was Ͻ8%. These observers were blind for clinical characteristics of the subjects and their ACE genotype. LVM was calculated following guidelines of the American Society of Echocardiography Convention, where end-diastolic measurements are made from the leading-edge to the leading-edge at the onset of the QRS complex. In each patient, interventricular septum (IVS), end-diastolic left ventricular internal dimension (LVID) and end-diastolic posterior wall thickness (PWT) were measured on three different cardiac cycles. The mean value of the three readings was used to calculate LVM using the following formula 34 :
LVM was indexed by body surface area to obtain left ventricular mass index (LVMI) expressed in g/m 2 . Posterior relative wall thickness (PWT) was calculated with the formula 23 :
Statistical analysis
The differences between the continuous quantitative variables were analysed by one-way analysis of variance and the multiple comparisons by the Tukey test. Ordinal variables were analysed by the nonparametric Kruskal-Wallis test and dichotomous variables by the 2 test. The associations between the I/D polymorphism with LVMI and RWT were studied by one-way analysis of variance. To determine whether a specific class of antihypertensive drug had a different influence on LVMI or RWT depending of the I/D ACE genotype, five independent one-way analysis of variance were performed (patients taking diuretics, patients on betablockers, on ACE inhibitors, on calcium channelblockers and subjects taking alpha-blockers). In each analysis only the patients taking that type of drug were included. The differences of LVMI in relation to the type of antihypertensive drug within a subgroup were analysed by a t-test. A P value Ͻ0.05 was considered statistically significant.
Results
Of the 96 patients enrolled only 82 were suitable for the study; 11 patients were excluded from the study after the echocardiographic study proved to be inadequate to calculate LVM with confident degree of accuracy. One patient was excluded because of a significant aortic insufficiency and another due to the presence of a dilated cardiomyopathy. One additional patient was excluded because he had stopped antihypertensive medications prior to the study.
Of the 82 patients studied (aged from 20 to 67), 39 had genotype DD, 33 had ID and 10 genotype II. The distribution was in Hardy-Weinberg equilibrium. Several clinical characteristics of the patients that were considered of interest were recorded. Twenty-five patients were smokers: 11 of the DD group (28%), 11 from the ID group (33%) and three from the II group (30%). Four patients had a medical history of peripheral occlusive arterial disease, one of whom had undergone surgery for an abdominal aneurysm. Of these subjects, one was DD, two were ID and the other was II. Ten patients had a history of cerebrovascular disease (six DD, three ID and one II). None of the 82 patients had clinical history of coronary heart disease or congestive heart failure. Seven patients had serum creatinine above 130 mol/L (one DD, five ID and one II), three of whom had proteinuria of Ͼ0.5 g/24 h (1 DD, and 2 ID).
The time of evolution of hypertension varied from 1 to 372 months, with a median of 60 months in the whole group. The period of treatment ranged from 1 to 372 months, with a median of 30 months in the whole group. There were no statistically significant differences between II, ID and DD patients regarding age, body mass index, body surface area, evolution and period of treatment between the three subgroups. In reference to the control degree of blood pressure, 38 patients were under optimal control, in 20 patients control was suboptimal and in 24 it was insufficient. No differences were detected among the DD, ID and II groups. Thirty-one patients (38%) were on monotherapy, whereas 29 patients (35%), 17 patients (21%) and five patients (6%) were taking, respectively, two, three and four drugs. Thirty patients (37%) were taking diuretics, 19 (23%) were on beta-blockers, 48 (59%) on ACE inhibitors, 49 (60%) on calcium-channel blockers and 11 (13%) were receiving alpha-blockers. Only one patient was taking clonidine in the context of a triple therapy. No statistically significant differences were detected among the three I/D ACE groups with respect to the number of antihypertensive drugs or to the relative proportion of each of the five major classes of antihypertensive drugs.
LVMI and RWT values are shown in Table 1 . There were no differences among the values of the three different groups (DD, ID, II). The presence of LVH was defined using the Cornell criteria for men (LVMI Ͼ134 g/m ) and also by the Framingham cri- ). Twenty-eight patients (34%) had LVH defined by the Cornell criteria and 32 (39%) by the Framingham criteria. No differences were found in prevalence of LVH between the three I/D ACE groups for either of the two criteria ( Table  2 ). The distribution of I/D ACE genotypes was similar in the whole group of patients with hypertension, in the group of patients with hypertension and LVH, and in the control group (see Table 3 ).
We also investigated whether patients who were taking ACE inhibitors had a lower LVMI than patients who were not taking this kind of antihypertensive drug but, again, no differences were detected. The analysis was repeated comparing LVMI of the three groups (DD, ID or II) of patients who were on ACE inhibitors but no differences were observed. This strategy was repeated for each pharmacological group: diuretics, beta-blockers, calcium-channel antagonists and alpha-blockers. In the groups of patients taking diuretics and beta-blockers the analysis was done between the DD and the ID subgroups, because there were no II patients taking these kind of drugs. No significant differences were detected in these analysis.
Discussion
Shunckert et al 20 reported the association between electrocardiographically determined LVH and the DD genotype. This relationship was particularly strong in the group of normotensive men. Since then, various studies have analysed this association using different methods and in different populations but results have been contradictory. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The discrepancies between the results of the studies performed in patients with hypertension and LVH could be due, at least in part, to the use of different methods to assess LVH, different genetic back-ground of the populations, or differences in severity of hypertension and/or in the use of type antihypertensive therapies. In consequence, we decided, first, to measure LVM by echocardiography (2D guided M-mode) and to express the results indexed by total body surface. This method is the most accurate to measure LVM and was used in most of the studies that identified LVH as an independent cardiovascular risk factor. Second, we studied only males from an ethnically homogeneous population in an attempt to avoid the biases related to genetic background and gender. Third, we selected pharmacologically treated patients with essential hypertension, which is the vast majority of hypertensives.
Our results did not show either a higher LVMI or RWT in the patients of the DD genotype. Furthermore, the distribution of the D and I alleles in our study group was similar to that of healthy controls and that reported for the general population. As in many negative studies, in our study type II error can not be discarded. We calculated sample size from the differences detected among the first 10 patients included in the study. Even though the final results of the study seem somewhat underpowered, the complete absence of any kind of tendencies make us think that differences are not present.
It has recently been reported that ACE inhibitors could have a greater effect on LVH regression in subjects with DD genotype. 31 In spite of our limited sample size, as many as 59% of our patients were taking ACE inhibitors and for this reason we decided to perform a subanalysis comparing LVMI between patients taking ACE inhibitors of the DD group against the other two subgroups. LVMI in the DD subgroup was not different than those of patients taking other kinds of drugs. Therefore, our results do not support that the lack of differences in LVM between the three ACE genotypes is due to higher regression of LVH in the patients with the D allele and treated with ACE inhibitors.
In summary, our results do not support that the determination of the ACE genotype could help in the identification of patients with treated essential hypertension at higher risk of LVH. Prospective and more powered studies will be needed to gain definitive insight on the capability of different types of antihypertensive drug treatments to cause regression of LVH.
